Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.

Novo Nordisk (NVO) will invest $4.1B to build a second fill and finish manufacturing facility in Clayton, N.C. focused on injectables medications, including current and future ones for obesity.
The development comes as Novo, which makes the weight loss drug Wegovy (semaglutide), and rival Eli Lilly (LLY), which markets Zepbound (tirzepatide), are both experiencing supply constraints due to high demand for the treatments.
The Danish drugmaker said the new plant will add 1.4M additional square feet of production space.
Once finished between 2027 and 2029, the building is expected to add 1,000 new jobs. Novo already has ~2,500 employees in the area.
The drugmaker noted that this year, it plans to invest $6.8B to increase production overall.